Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: In their cost-effective analysis of screening bone densitometry followed by alendronate therapy for older men diagnosed with osteoporosis, Dr Schousboe and colleagues1 conclude that mass screening may be cost-effective for men aged 65 years or older with a prior clinical fracture and for men aged 80 to 85 years without a prior fracture. However, the Markov model used in their analysis does not consider functional status to define the base-case population and the health states.
Ito K. Bone Densitometry and Treatment for Osteoporosis in Older Men. JAMA. 2007;298(18):2136-2137. doi:10.1001/jama.298.18.2136